Asian Fund for Cancer Research Limited, shared a post by Global Coalition for Adaptive Research, on LinkedIn, adding:
“On Glioblastoma Awareness Day, we recognize the urgent need for continued progress in glioblastoma research. We’re sharing the latest update from the Global Coalition for Adaptive Research on GBM AGILE.”
Quoting Global Coalition for Adaptive Research‘s post:
“Five days.
That’s all it took to go from first site activated to first patient randomized.
This milestone reflects what’s possible when clinical trials are designed as systems of continuous learning. Instead of building a new trial for every question or investigational therapy, GBM AGILE efficiently reduces timelines to learn faster – accelerating the path from discovery to patient impact.
The first patients have been randomized and dosed to the tinostamustine arm on GBM AGILE, marking an important step forward for patients and the future of more efficient clinical research.
Read the announcement.”